Melanoma is one of the deadliest skin cancers. While survival rates for people diagnosed with melanoma are generally high, they decrease dramatically once the cancer spreads to other parts of the body. Melanoma accounts for only 4 percent of skin cancer diagnoses, but is responsible for 80 percent of skin-cancer deaths. Unfortunately, melanoma's ability to spread is a unique characteristic of this cancer.
Recognizing the need to accelerate research that develops clinical breakthroughs in the prevention, diagnosis and treatment of melanoma, Mike Milken joined with leading cancer researchers and philanthropists in 2007 to create the Melanoma Research Alliance (MRA). The MRA is focused on finding and funding the most promising melanoma research worldwide that will accelerate progress toward a cure. MRA supports research that will translate into the best options for patients - in prevention, diagnosis, prognosis, and treatment.
In February 2009, a little more than a year after its inception, MRA convened its first scientific retreat and brought together 100 of the world's leading melanoma researchers. The retreat facilitated early sharing of data with the potential to make transforming advances in the biology and treatment of melanoma. With generous support from Debra and Leon Black, the Melanoma Research Alliance funds grants to young investigators, established investigators and research teams.
| |
|
